725 related articles for article (PubMed ID: 26352815)
1. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Garfall AL; Maus MV; Hwang WT; Lacey SF; Mahnke YD; Melenhorst JJ; Zheng Z; Vogl DT; Cohen AD; Weiss BM; Dengel K; Kerr ND; Bagg A; Levine BL; June CH; Stadtmauer EA
N Engl J Med; 2015 Sep; 373(11):1040-7. PubMed ID: 26352815
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
5. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells in Myeloma.
Shimabukuro-Vornhagen A; Schloesser HA; von Bergwelt-Baildon MS
N Engl J Med; 2016 Jan; 374(2):193-4. PubMed ID: 26760101
[No Abstract] [Full Text] [Related]
7. Chimeric Antigen Receptor T Cells in Myeloma.
Garfall AL; Stadtmauer EA; June CH
N Engl J Med; 2016 Jan; 374(2):194. PubMed ID: 26760100
[No Abstract] [Full Text] [Related]
8. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
9. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
[TBL] [Abstract][Full Text] [Related]
11. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation.
Kiel K; Cremer FW; Rottenburger C; Kallmeyer C; Ehrbrecht E; Atzberger A; Hegenbart U; Goldschmidt H; Moos M
Bone Marrow Transplant; 1999 May; 23(10):1019-27. PubMed ID: 10373068
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
13. Sending CAR T Cells After Multiple Myeloma.
Cancer Discov; 2017 Aug; 7(8):OF9. PubMed ID: 28588060
[TBL] [Abstract][Full Text] [Related]
14. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome.
Xia L; Wang Y; Li T; Hu X; Chen Q; Liu L; Jiang B; Li C; Wang H; Wang S; Yang G; Bao Y
Cancer Med; 2019 Jun; 8(6):2930-2941. PubMed ID: 31050207
[TBL] [Abstract][Full Text] [Related]
15. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
17. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
18. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
19. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
[TBL] [Abstract][Full Text] [Related]
20. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]